UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

 

 

iTeos Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

46565G104

(CUSIP Number)

Luke Evnin

MPM Asset Management

450 Kendall Street

Cambridge, MA 01242

Telephone: (617) 425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 6, 2021

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2014, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,631,972

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,631,972

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,631,972

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  4.6%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This schedule is filed by MPM BioVentures 2014, L.P. (“BV 2014”), MPM BioVentures 2014 (B), L.P. (“BV 2014(B)”), MPM Asset Management Investors BV2014 LLC (“AM BV2014 LLC”), MPM BioVentures 2018, L.P. (“BV 2018”), MPM BioVentures 2018 (B), L.P. (“BV 2018(B)”), MPM Asset Management Investors BV2018 LLC (“AM BV2018 LLC”), UBS Oncology Impact Fund L.P. (“UBS Oncology”), MPM BioVentures 2014 GP LLC (“BV 2014 GP”), MPM BioVentures 2014 LLC (“BV 2014 LLC”), MPM BioVentures 2018 GP LLC (“BV 2018 GP”), MPM BioVentures 2018 LLC (“BV 2018 LLC”), Oncology Impact Fund (Cayman) Management LP (“Oncology Cayman”) and BioImpact Capital LLC (“BioImpact”) (collectively, the “MPM Entities”) and Ansbert Gadicke, Luke Evnin, Todd Foley and Edward Hurwitz (collectively, the “Listed Persons” and together with the MPM Entities, the “Filing Persons”). The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of iTeos Therapeutics, Inc. (the “Issuer”), as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 2


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2014 (B), L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  97,289

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  97,289

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  97,289

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.3%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 3


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM Asset Management Investors BV2014 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  56,172

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  56,172

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  56,172

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.2%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 4


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2018, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,030,718

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,030,718

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,030,718

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  2.9%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 5


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2018 (B), L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  48,966

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  48,966

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  48,966

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.1%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 6


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM Asset Management Investors BV2018 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  20,353

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  20,353

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  20,353

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  0.1%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 7


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  UBS Oncology Impact Fund, L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Cayman Islands

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,844,727

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,844,727

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,844,727

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.2%(2)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 8


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2014 GP LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,729,261(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,729,261(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,729,261(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  4.9%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,631,972 shares held by BV 2014 and 97,289 shares held by BV 2014(B). BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B).

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 9


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2014 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,785,433(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,785,433(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,785,433(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.1%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,631,972 shares held by BV 2014, 97,289 shares held by BV 2014(B) and 56,172 shares held by AM BV2014 LLC. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014 LLC

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 10


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2018 GP LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,079,684(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,079,684(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,079,684(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.1%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,030,718 shares held by BV 2018 and 48,966 shares held by BV 2018(B). BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B).    

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 11


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  MPM BioVentures 2018 LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,100,037(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,100,037(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,100,037(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.1%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,030,718 shares held by BV 2018, 48,966 shares held by BV 2018(B) and 20,353 shares held by AM BV2018 LLC. BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018 LLC.    

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 12


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  Oncology Impact Fund (Cayman) Management LP

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Cayman Islands

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,844,727(2)

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,844,727(2)

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,844,727(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  PN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2)

Consists of shares held by UBS Oncology. BioImpact is the General Partner of Oncology Cayman, the General Partner of UBS Oncology.

 

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 13


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  BioImpact Capital LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  1,844,727(2)

     8.   

  Shared Voting Power

 

  0

     9.   

  Sole Dispositive Power

 

  1,844,727(2)

   10.   

  Shared Dispositive Power

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,844,727(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  5.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  OO

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Consists of shares held by UBS Oncology. BioImpact is the general partner Oncology Cayman, the General Partner of UBS Oncology.

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 14


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  Ansbert Gadicke

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  4,730,197(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  4,730,197(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  4,730,197(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  13.4%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes 1,631,972 shares held by BV 2014, 97,289 shares held by BV 2014(B), 56,172 shares held by AM BV2014 LLC, 1,030,718 share held by BV 2018, 48,966 shares held by BV 2018(B), 20,353 shares held by AM BV2018 LLC and 1,844,727 shares held by UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV2018 LLC and the managing partner of BioImpact.

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 15


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  Luke Evnin

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  2,855,470(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  2,855,470(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,855,470(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  8.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2)

Includes 1,631,972 shares held by BV 2014, 97,289 shares held by BV 2014(B), 56,172 shares held by AM BV2014 LLC, 1,030,718 share held by BV 2018, 48,966 shares held by BV 2018(B) and 20,353 shares held by AM BV2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

 

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 16


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  Todd Foley

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  2,855,470(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  2,855,470(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  2,855,470(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  8.2%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2)

Includes 1,631,972 shares held by BV 2014, 97,289 shares held by BV 2014(B), 56,172 shares held by AM BV2014 LLC, 1,030,718 share held by BV 2018, 48,966 shares held by BV 2018(B) and 20,353 shares held by AM BV2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

 

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 17


CUSIP No. 46565G104

 

  1.    

   Name of Reporting Persons.

 

  Edward Hurwitz

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒ (1)

 

  3.  

  SEC USE ONLY

 

  4.  

  Source of Funds (See Instructions)

 

  OO

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With:

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  1,100,037(2)

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  1,100,037(2)

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  1,100,037(2)

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  3.1%(3)

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 

(1)

This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2)

Includes 1,030,718 shares held by BV 2018, 48,966 shares held by BV 2018(B) and 20,353 shares held by AM BV2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

 

(3)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

 

Page 18


This Amendment No. 3 to Schedule 13D (“Amendment No. 2”) is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the “Common Stock”), of iTeos Therapeutics Inc. (the “Issuer”), as filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2020 and, as amended by Amendment No. 1 filed September 21, 2021 and Amendment No. 2 filed October 19, 2021 (as amended, the “Original Schedule 13D”). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales and distributions in kind of the Issuer’s Common Stock by certain Filing Persons.

Items 4, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 3 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

 

Item 4.

Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

The MPM Entities sold an aggregate of 617,640 shares of Common Stock in open market transactions from October 7, 2021 through December 7, 2021 for aggregate gross proceeds of $19,939,210. On November 17, 2021, BV 2014(B) distributed an aggregate of 10,424 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration and BV 2018(B) distributed an aggregate of 5,247 shares of Common Stock in a pro rata in-kind distribution to its limited partners for no consideration.

 

Item 5.

Interest in Securities of the Issuer

(a) – (b) The following information with respect to the ownership of the Common Stock of the Issuer by the Filing Persons is provided as of December 7, 2021:

 

Reporting Person

   Shares
Held
Directly
     Sole Voting
Power
     Shared
Voting
Power
     Sole
Dispositive
Power
     Shared
Dispositive
Power
     Beneficial
Ownership
     Percentage
of Class (1)
 

BV 2014

     1,631,972        1,631,972        0        1,631,972        0        1,631,972        4.6

BV 2014(B)

     97,289        97,289        0        97,289        0        97,289        0.3

AM BV2014 LLC

     56,172        56,172        0        56,172        0        56,172        0.2

BV 2018

     1,030,718        1,030,718        0        1,030,718        0        1,030,718        2.9

BV 2018(B)

     48,966        48,966        0        48,966        0        48,966        0.1

AM BV2018 LLC

     20,353        20,353        0        20,353        0        20,353        0.1

UBS Oncology

     1,844,727        1,844,727        0        1,844,727        0        1,844,727        5.2

BV 2014 GP(2)

     0        0        1,729,261        0        1,729,261        1,729,261        4.9

BV 2014 LLC(3)

     0        0        1,785,433        0        1,785,433        1,785,433        5.1

BV 2018 GP(4)

     0        0        1,079,684        0        1,079,684        1,079,684        3.1

BV 2018 LLC(5)

     0        0        1,100,037        0        1,100,037        1,100,037        3.1

Oncology Cayman(6)

     0        0        1,844,727        0        1,844,727        1,844,727        5.2

BioImpact(6)

     0        0        1,844,727        0        1,844,727        1,844,727        5.2

Ansbert Gadicke(7)

     0        0        4,730,197        0        4,730,197        4,730,197        13.4

Luke Evnin(8)

     0        0        2,885,470        0        2,885,470        2,885,470        8.2

Todd Foley(8)

     0        0        2,885,470        0        2,885,470        2,885,470        8.2

Edward Hurwitz(9)

     0        0        1,100,037        0        1,100,037        1,100,037        3.1

 

Page 19


(1)

This percentage is calculated based upon 35,273,893 outstanding shares of common stock of the Issuer, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2021.

(2)

Includes securities held by BV 2014 and BV 2014(B). BV 2014 GP is the direct general partner of BV 2014 and BV 2014(B).

(3)

Includes securities held by BV 2014, BV2014(B) and AM BV2014 LLC. BV 2014 LLC is the indirect general partner of BV 2014 and BV 2014(B) and the manager of AM BV2014 LLC.

(4)

Includes securities held by BV 2018 and BV 2018(B). BV 2018 GP is the direct general partner of BV 2018 and BV 2018(B).

(5)

Includes securities held by BV 2018, BV 2018(B) and AM BV2018 LLC. BV 2018 LLC is the indirect general partner of BV 2018 and BV 2018(B) and the manager of AM BV2018 LLC.

(6)

Includes shares held by UBS Oncology. BioImpact is the General Partner of Oncology Cayman, the General Partner of UBS Oncology.

(7)

Includes securities held by BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B), AM BV2018 LLC and UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC and the managing partner of BioImpact.

(8)

Includes securities held by BV 2014, BV 2014(B), AM BV2014 LLC, BV 2018, BV 2018(B), and AM BV2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

(9)

Includes shares held by BV 2018, BV 2018(B) and AM BV2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

Each Filing Person disclaims membership in a “group.” Each Filing Person also disclaims beneficial ownership of any shares of the Issuer, except for the shares set forth in the table above next to the respective Filing Person’s name in subsection (b) of this Item 5.

 

Page 20


The Reporting Persons sold the following Common Stock in the open market in the sixty days preceding the date of this filing:

 

Date of Sale

   Price Range      Average
Price
     Sold by
BV 2014
     Sold by
AM
BV2014
LLC
     Sold by
BV 2018
     Sold by
AM
BV2018
LLC
     Sold by UBS
Oncology
 

10/7/2021

   $ 26.95-$27.07      $ 27.00        684        24        432        9        773  

10/8/2021

   $ 26.97-$27.035      $ 27.01        1,210        42        765        15        1,368  

10/11/2021

   $ 26.95-$27.53      $ 27.24        29,081        1,001        18,367        363        32,872  

10/12/2021

   $ 26.95-$27.28      $ 27.09        5,077        175        3,206        63        5,739  

10/13/2021

   $ 26.95-$27.335      $ 27.13        12,469        429        7,875        156        14,094  

10/14/2021

   $ 26.95-$27.84      $ 27.30        16,277        560        10,280        203        18,399  

10/15/2021

   $ 26.97-$27.955      $ 27.53        5,298        182        3,347        66        5,989  

10/15/2021

   $ 27.97-$28.07      $ 28.01        1,215        42        767        15        1,374  

10/18/2021

   $ 26.96-$27.94      $ 27.14        3,676        125        2,321        45        4,153  

11/22/2021

   $ 36.58-$37.555      $ 37.16        5,545        191        3,502        69        6,268  

11/22/2021

   $ 37.58-$38.16      $ 37.81        7,034        242        4,443        88        7,951  

11/23/2021

   $ 35.46-$36.45      $ 36.21        11,704        403        7,392        146        13,231  

11/23/2021

   $ 36.48-$36.52      $ 36.50        214        7        135        3        241  

11/24/2021

   $ 34.82-$35.78      $ 35.20        2,900        100        1,832        36        3,279  

11/24/2021

   $ 35.83-$36.81      $ 36.05        10,929        376        6,902        136        12,353  

11/24/2021

   $ 36.85-$37.27      $ 37.02        7,820        269        4,939        98        8,839  

11/26/2021

   $ 34.915-$35.91      $ 35.49        3,899        134        2,463        49        4,407  

11/26/2021

   $ 35.92-$36.39      $ 36.03        3,652        126        2,306        45        4,129  

11/29/2021

   $ 34.06-$34.86      $ 34.46        6,001        207        3,790        75        6,783  

11/29/2021

   $ 35.125-35.67      $ 35.37        178        6        112        2        202  

11/30/2021

   $ 33.93-$34.92      $ 34.62        3,494        120        2,206        41        3,948  

11/30/2021

   $ 34.93-$35.465      $ 35.19        16,733        576        10,569        198        18,916  

12/1/2021

   $ 33.26-$34.22      $ 33.82        3,600        124        2,274        44        4,069  

12/1/2021

   $ 34.30-$35.17      $ 34.61        3,251        112        2,053        41        3,674  

12/1/2021

   $ 35.30-$35.77      $ 35.34        534        18        337        7        604  

12/2/2021

   $ 33.19-$34.17      $ 33.74        17,728        611        11,197        221        20,039  

12/2/2021

   $ 34.25-$35.14      $ 34.83        4,427        152        2,796        55        5,004  

12/3/2021

   $ 34.15-$35.135      $ 34.68        10,467        359        6,612        131        11,833  

12/3/2021

   $ 35.15-$36.06      $ 35.44        1,441        50        910        18        1,628  

12/3/2021

   $ 36.26      $ 36.26        107        4        67        1        121  

12/6/2021

   $ 31.98-$32.975      $ 32.35        5,046        173        3,187        63        5,704  

12/6/2021

   $ 32.99-$33.98      $ 33.57        698        24        441        8        789  

12/6/2021

   $ 34-34.125      $ 34.08        303        10        191        4        342  

12/6/2021

   $ 35.04      $ 35.04        35        2        22        1        40  

12/7/2021

   $ 32.84-$33.75      $ 33.15        10,701        368        6,759        134        12,097  

12/7/2021

   $ 33.875-$34.25      $ 34.11        890        31        562        11        1,005  
           214,318        7,375        135,359        2,660        242,257  

The information provided and incorporated by reference in Item 3 and Item 6 is hereby incorporated by reference in this Item 5.

 

  (d)

Inapplicable.

 

  (e)

Inapplicable.

 

Item 7.

Material to Be Filed as Exhibits

 

C.

Agreement regarding filing of joint Schedule 13D.

 

Page 21


Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 9, 2021

 

MPM BIOVENTURES 2014, L.P.
By:   MPM BioVentures 2014 GP LLC,
  its General Partner
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2014 (B), L.P.
By:   MPM BioVentures 2014 GP LLC,
  its General Partner
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM ASSET MANAGEMENT INVESTORS BV2014 LLC
By:   MPM BioVentures 2014 LLC,
  Its Manager
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2014 GP LLC
By:   MPM BioVentures 2014 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director

 

Page 22


MPM BIOVENTURES 2014 LLC
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018, L.P.
By:   MPM BioVentures 2018 GP LLC,
  its General Partner
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018 (B), L.P.
By:   MPM BioVentures 2018 GP LLC,
  its General Partner
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
By:   MPM BioVentures 2018 LLC,
  Its Manager
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018 GP LLC
By:   MPM BioVentures 2018 LLC,
  Its Managing Member
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director
MPM BIOVENTURES 2018 LLC
By:  

/s/ Luke Evnin

Name:   Luke Evnin
Title:   Managing Director

 

Page 23


UBS ONCOLOGY IMPACT FUND, L.P.
By:   Oncology Impact Fund (Cayman) Management L.P.,
  its General Partner
By:   BioImpact Capital LLC
  Its General Partner
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.
By:   BioImpact Capital LLC
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
BIOIMPACT CAPITAL LLC
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
Title:   Managing Partner
By:  

/s/ Todd Foley

Name:   Todd Foley
By:  

/s/ Luke Evnin

Name:   Luke Evnin
By:  

/s/ Ansbert Gadicke

Name:   Ansbert Gadicke
By:  

/s/ Edward Hurwitz

Name:   Edward Hurwitz

 

Page 24


Schedule I

General Partners/Members

Ansbert Gadicke

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC, MPM BioVentures 2018 LLC and managing partner of BioImpact Capital LLC.

Citizenship: USA

Luke Evnin

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.

Citizenship: USA

Todd Foley

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC.

Citizenship: USA

Edward Hurwitz

c/o MPM Asset Management

450 Kendall Street

Cambridge, MA 02142

Principal Occupation: Managing director of MPM BioVentures 2018 LLC.

Citizenship: USA

 

Page 25


Exhibit Index

 

C.

Agreement regarding filing of joint Schedule 13D.

 

Page 26

iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more iTeos Therapeutics Charts.
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more iTeos Therapeutics Charts.